Autres langues Kane Biotech Inc.

Actions

KNE

CA4838092084

Marché Fermé - Toronto S.E. Autres places de cotation 15:30:00 15/07/2024			Varia. 5j.	Varia. 1 janv.
0,145 ^CAD	+3,57 %		-3,33 %	+81,25 %

11/07	Kane Biotech signe un accord de licence avec Omni Bioceutical pour ses produits de soins du cuir chevelu	MT
11/07	Kane Biotech signe un accord de licence mondial avec Omni Bioceutical Innovations Inc.	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Kane Biotech Announces Issuance of Restricted Share Units	15/07
Kane Biotech Signs a License Agreement with Omni Bioceutical For Its Scalp Care Products	11/07
Kane Biotech Signs Worldwide License Agreement with Omni Bioceutical Innovations Inc.	11/07
Kane Biotech Signs Worldwide License Agreement with Omni Bioceutical Innovations Inc	11/07
Kane Biotech Completes First Commercial Sale of revyve Antimicrobial Wound Gel	27/06
Kane Biotech Completes First Commercial Sale of revyve Antimicrobial Wound Gel to ProgenaCare Global	27/06
Kane Biotech Brief: Says Made First Commercial Sale of revyve Antimicrobial Wound Gel to ProgenaCare Global	27/06
Kane Biotech Makes First Commercial Sale of revyve™ Antimicrobial Wound Gel to ProgenaCare Global	27/06
Kane Biotech Makes First Commercial Sale of revyve? Antimicrobial Wound Gel to ProgenaCare Global	27/06
Kane Biotech Signs License Agreement with I-MED Pharma	25/06
Kane Biotech Signs Worldwide License Agreement with Montreal-Based I-MED Pharma Inc.	25/06
Kane Biotech Signs Worldwide License Agreement with I-MED Pharma Inc	25/06
Kane Biotech Q1 Loss Widens Despite Revenue Gains; to Report a Q2 Gain Following Sale of STEM Animal Health	23/05
Kane Biotech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	23/05
Kane Biotech Announces First Quarter 2024 Financial Results	23/05
Kane Biotech to Release First Quarter 2024 Financial Results on May 23, 2024	16/05
Kane Biotech Expands Wound Care Portfolio with Patented Schultz Biofilm Wound Map	15/05
Kane Biotech Expands its Wound Care Portfolio with Patented Schultz Biofilm Wound Map	15/05
Kane Biotech Expands its Wound Care Portfolio with Patented Schultz Biofilm Wound Map	15/05
Kane Biotech to Host Investor Webinar	16/04

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Kane Biotech Inc.

Actions

KNE

CA4838092084

Autres langues

Filtres